Identity and synonyms
Search collisions include CardioGen-82 radiotracer generators and research networks; these are excluded.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Mechanism
Commercial bioregulator whose name suggests cardiac tropism; the name does not establish a clinical cardiac target.
Evidence and critical reading
Reported scientific and empirical uses
Cardiovascular and vascular function
Included because it is offered as a bioregulator, preserving the distinction between an organ narrative and therapeutic demonstration.
Human evidence
The located primary paper studied transplanted M-1 sarcoma in senescent rats and apoptosis/necrosis changes. It was not a human cardiovascular trial.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
The located primary paper studied transplanted M-1 sarcoma in senescent rats and apoptosis/necrosis changes. It was not a human cardiovascular trial.
The located primary paper studied transplanted M-1 sarcoma in senescent rats and apoptosis/necrosis changes. It was not a human cardiovascular trial.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
No human regimen or clinical interaction profile was defined here. An animal tumor effect does not authorize oncology or cardiac use.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID20396706 · Animal experiment
Senescent rats with M-1 sarcoma.
Animal experiment.
Tumor apoptosis/necrosis changes.
Not a human cardiac trial; no demonstrated oncology indication.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Cardiogen · 1 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT01424774 · Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI ScanningRegistry status: CompletedLast update posted: August 15, 2012Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID20396706
Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats.
Levdik NV, Knyazkin IV.
October 16, 2026
- SEARCH-PUBMED-cardiogen
PubMed/MED targeted search: TITLE_ABS:cardiogen AND (TITLE_ABS:peptide OR TITLE_ABS:Khavinson)
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026